Jacques Séguin

Devax, Inc. is a private, emerging medical device company developing a proprietary bifurcated stent system that is intended to provide a clinical solution to treat atherosclerotic disease in coronary bifurcations and left main coronary arteries. Coronary artery disease continues to be the number one cause of death in the United States and Europe. The Company believes there is significant potential for its unique stent system to serve as a platform technology to address and provide tailored care for bifurcations wherever they occur including those found in carotid and peripheral vascular disease. Devax is headquartered in Lake Forest, California.

Stentys SA engages in the design, development, and marketing of self-expanding stents used in treating cardiovascular diseases. It provides solutions for the treatment of acute myocardial infarction and other complex coronary diseases. Its products include Xposition S, Devoir, AmazoniaSir, stemiCath, Yangtzenano and YangtzeNC. The company was founded by Gonzague Issenmann and Jacques Seguin on July 6, 2006 and is headquartered in Neuilly-sur-Seine, France.

Emanate Biomedical, Inc. is an American healthcare technology company that is transforming the standard of care for oral diseases and wounds. Emanate is headquartered in an undisclosed location with a dedicated R&D center in the area and is backed by leading healthcare technology investors. Emanate's patented technology involves personalized single-use preloaded hydrogel-infused dental trays that will improve outcomes with personalized treatment. The company is currently enrolling patients in a clinical study for its first application at the Forsyth Institute in MA. The company was founded by Peter Zegarelli and Jarret Fass, with Jarret Fass serving as the CEO since incorporation.